Search details
1.
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).
Breast Cancer Res Treat
; 169(3): 537-548, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29455298
2.
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Cancer
; 123(13): 2444-2451, 2017 Jul 01.
Article
in English
| MEDLINE | ID: mdl-28464211
3.
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Breast Cancer Res Treat
; 164(3): 571-580, 2017 Aug.
Article
in English
| MEDLINE | ID: mdl-28484925
4.
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Breast Cancer Res Treat
; 156(2): 343-9, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-27006189
5.
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Breast Cancer Res Treat
; 157(1): 101-8, 2016 05.
Article
in English
| MEDLINE | ID: mdl-27116182
6.
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
Breast Cancer Res Treat
; 153(2): 353-60, 2015 Sep.
Article
in English
| MEDLINE | ID: mdl-26276354
7.
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Lancet Oncol
; 15(4): 474-82, 2014 Apr.
Article
in English
| MEDLINE | ID: mdl-24636210
8.
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.
Breast Cancer Res
; 16(1): R8, 2014 Jan 22.
Article
in English
| MEDLINE | ID: mdl-24451146
9.
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.
J Clin Oncol
; : JCO2400835, 2024 Jun 02.
Article
in English
| MEDLINE | ID: mdl-38824432
10.
Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
Breast Cancer Res
; 15(4): R71, 2013.
Article
in English
| MEDLINE | ID: mdl-23972025
11.
Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
J Natl Cancer Inst
; 110(12): 1370-1379, 2018 12 01.
Article
in English
| MEDLINE | ID: mdl-30239794
12.
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.
J Natl Cancer Inst
; 110(9): 1003-1008, 2018 09 01.
Article
in English
| MEDLINE | ID: mdl-29554282
13.
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
J Natl Cancer Inst
; 110(12): 1360-1369, 2018 12 01.
Article
in English
| MEDLINE | ID: mdl-29718314
14.
Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment.
BMC Cancer
; 7: 31, 2007 Feb 20.
Article
in English
| MEDLINE | ID: mdl-17311683
15.
Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment.
BMC Cancer
; 7: 174, 2007 Sep 10.
Article
in English
| MEDLINE | ID: mdl-17845726
16.
Competing Risks of Mortality by PAM50 Intrinsic Subtype of British Columbia Tamoxifen-Treated Cohort of Postmenopausal Patients With Breast Cancer.
Clin Breast Cancer
; 17(4): e215-e224, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28365335
17.
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
Cancer Res
; 76(23): 7012-7023, 2016 12 01.
Article
in English
| MEDLINE | ID: mdl-27758888
18.
A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.
Springerplus
; 4: 631, 2015.
Article
in English
| MEDLINE | ID: mdl-26543765
19.
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
J Clin Oncol
; 33(3): 265-71, 2015 Jan 20.
Article
in English
| MEDLINE | ID: mdl-25512454
20.
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
J Clin Oncol
; 33(14): 1574-83, 2015 May 10.
Article
in English
| MEDLINE | ID: mdl-25779558